- 1
- 2
- 3
- 4
Executive Outlook: Converting Innovative Science Into Predictable Returns
- 1
- 2
- 3
- 4
Finance And Funding: Anticipating Improvement, Planning For Uncertainty
- 1
- 2
- 3
- 4
Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place
ALSO IN THIS MONTH'S ISSUE
-
![Top 2024 Clinical Trial Site Challenges]( "Top 2024 Clinical Trial Site Challenges: Staffing & Technology")
Top 2024 Clinical Trial Site Challenges: Staffing & TechnologyIndustry experts talk about some of the new challenges facing clinical trial sites in 2024.
-
![Bio_Matt article_450x300]( "Accelerating Drug Development With Real World Data")
Accelerating Drug Development With Real World DataThink real-world data’s only application is clinical trials? Think again. Savvy early-stage biotechs are leveraging RWD in their formative stages, long before entering the clinic, to drive critical efficiencies in drug discovery and development.
-
![RNA OUTLOOK_Carsten Rudolph_450X300]( "Defining A Competitive Next-Gen RNA Therapeutic In 2024")
Defining A Competitive Next-Gen RNA Therapeutic In 2024To start singling-out where the opportunities exist to craft the next generation of RNA therapeutics, Anna Rose Welch sat down with four RNA executives.
-
![Biopharma’s Eminent Challenges Feature]( "Biopharma’s Eminent Challenges In 2024 — Inside & Out")
Biopharma’s Eminent Challenges In 2024 — Inside & OutA baker’s dozen of biopharma CEOs answer a call to prioritize and describe challenges they expect to face in the coming year.
WEB-EXCLUSIVE EDITORIAL
NEWSLETTER ARCHIVE
- 12.08.23 -- Will Funding And Financing Rebound Next Year?
- 12.08.23 -- New Episodes: RNA Delivery Business, Gene Therapy Deals, Steve Gorlin's Golden Rules, and more.
- 12.07.23 -- The Future Of Lipid Nanoparticles In Developing Cell And Gene Therapy
- 12.06.23 -- What's Next For RNA Therapeutics?
- 12.06.23 -- Navigating Clinical Trial Success With Risk-Based Monitoring Strategies
DECEMBER 2023 DIGITAL EDITION
LIFE SCIENCE LEADER CONTENT COLLECTIONS
2023 CMO & CRO AWARDS EDITION
ASK THE BOARD
- In September, You Testified Before Congress On The Inflation Reduction Act’s (IRA) Real-World Impact On Rare Disease R&D And Small Molecule Therapies. Can You Summarize The Key Points?
- What New Technologies Offer The Most Promise For Improving Global Supply Chain Operations?
- How Can Leaders Balance Requests Of Employees To Continue Remote Working With The Need For Increased Business Efficiency And Achieving Strong Dynamics Among A Management Team?
- Given Drug Development Time Horizons, How Does A Company Best Navigate The Inevitable Vagaries Of Investor Therapeutic/Modality Sentiment And Its Collateral Consequences On Funding?
- What Impact Is The Inflation Reduction Act Already Having On Biopharma Companies, And What More Can The Industry Do Going Forward?
- How Can Executives Work Through Tightened Budgets And Manage Tradeoffs While Keeping The Workforce Happy And Motivated?
This website uses cookies to ensure you get the best experience on our website. Learn more